Received Nov 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
three employees received one pediatric dose followed by one adult dose; three employees received one pediatric dose followed by one adult dose; This non-serious case was reported by a other health professional and described the occurrence of adult use of a child product in a adult patient who received HBV (Engerix B pediatric) for prophylaxis. On 07-NOV-2025, the patient received Engerix B pediatric. On 07-NOV-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: three employees received one pediatric dose followed by one adult dose) and underdose (Verbatim: three employees received one pediatric dose followed by one adult dose). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date :21-NOV-2025 The batch number was not provided and a request for this information has been made. This case has been linked with US2025145825, reported by the same reporter.; Sender's Comments: US-GSK-US2025145825: